LAVA Therapeutics Q1 2023 Earnings Report $1.03 +0.04 (+4.16%) (As of 12/20/2024 05:51 PM ET) Earnings HistoryForecast LAVA Therapeutics EPS ResultsActual EPS-$0.53Consensus EPS -$0.49Beat/MissMissed by -$0.04One Year Ago EPSN/ALAVA Therapeutics Revenue ResultsActual Revenue$1.22 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ALAVA Therapeutics Announcement DetailsQuarterQ1 2023Date6/8/2023TimeQ1 2023 Earnings ReleaseConference Call ResourcesLVTX Earnings History Buy this coin BEFORE Inauguration Day … (Ad)Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $125,000 by the end of his first month in office.This could be his favorite coin. LAVA Therapeutics Earnings HeadlinesQ1 Earnings Forecast for LVTX Issued By Leerink PartnrsDecember 17, 2024 | americanbankingnews.comLAVA Therapeutics' (LVTX) Market Perform Rating Reiterated at Leerink PartnersDecember 15, 2024 | americanbankingnews.comURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.December 21, 2024 | Crypto Swap Profits (Ad)LAVA Therapeutics (NASDAQ:LVTX) Rating Lowered to Hold at Leerink PartnrsDecember 15, 2024 | americanbankingnews.comLAVA Therapeutics (NASDAQ:LVTX) Cut to "Hold" at Citizens JmpDecember 14, 2024 | americanbankingnews.comLeerink Partners Downgrades LAVA Therapeutics N.V. (LVTX)December 13, 2024 | msn.comSee More LAVA Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like LAVA Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on LAVA Therapeutics and other key companies, straight to your email. Email Address About LAVA TherapeuticsLAVA Therapeutics (NASDAQ:LVTX) N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.View LAVA Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
